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Abstract
Extranodal spread (ENS) in patients with head and neck squamous cell carcinoma (HNSCC)
can greatly influence the prognostic outcomes. However, the relative risks of ENS in the
primary (1st) and secondary (2nd) metastatic nodes (mets) are not well documented. We ret-
rospectively analyzed the hazard ratios (HRs) of ENS in the 1st and 2nd mets from 516
HNSCC patients who had undergone primary tumor excision. The impact of clinically and/or
histologically confirmed ENS-positive mets on prognosis in terms of cancer-specific survival
was analyzed. Cox proportional hazard regression analysis indicated that ENS-positive 1st
met (adjusted HR = 3.15; 95% CI, 1.40–7.56; p = 0.006) and ENS-positive 2nd met (adjusted
HR = 4.03; 95% CI, 1.41–16.96; p = 0.007) significantly and independently predicted poor
prognosis; however, other variables including primary site, met size or numbers, and met
location in the contralateral side of the primary lesion, did not. Cumulative incidence function
and Cox analyses indicated that differences in ENS profiles of 1st and 2nd mets stratified
HNSCC patients with varying risks of poor outcome; HRs relative to patients with ENS-posi-
tive 1st met (-)/ENS-positive 2nd met (-) were 4.02 (95% CI, 1.78–8.24; p = 0.002), 8.29
(95% CI, 4.58–14.76; p <0.001), and 25.80 (95% CI, 10.15–57.69; p <0.001) for patients with
ENS-positive 1st met (+)/ENS-positive 2nd met (-), ENS-positive 1st met (-)/ENS-positive
2nd met (+), and ENS-positive 1st met (+)/ENS-positive 2nd met (+) patients, respectively.
Kaplan-Meier analysis indicated that the 2nd met that appeared in the neck side with a history
of 1st met and neck dissection had a higher risk of ENS than the 2nd met in the neck side
without the history (p = 0.003). These results suggested that ENS is a dominant prognostic
predictor of HNSCC patients, with double-positive ENS in the 1st and 2nd mets predicting the
most devastating outcome.
Introduction
Metastasis to the regional lymph node has been considered a critical risk factor in patients
with head and neck squamous cell carcinoma (HNSCC). A metastatic node (met) in the neck
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has been found to be closely related to the prognosis of HNSCC patients [1]. However, the
causal relationship between lymph node metastasis and poor prognosis of HNSCC patients
has not been well understood due to significant contributions of other demographic and clini-
cal factors to the prognostic outcomes of patients. Patient prognosis is further deteriorated by
extensions of metastatic cancer cells beyond the nodal capsule (extranodal spread, ENS),
which is frequently associated with high rate of locoregional and distant failures [2–5].
The development of secondary (2nd) met may occur after surgical excision of the primary
lesions without any locoregional failure of the primary site or distant metastasis, which could
further deteriorate the prognosis of patients. Also in such cases, the ENS would be an addi-
tional prognostic risk factor. Neck dissection (ND) may be performed for the primary (1st)
met(s) that was histologically confirmed on biopsy specimens and/or was suspected based on
imaging information without histological evidence. The lymphatic systems in the neck and the
microenvironment of the regional lymph nodes may be altered after surgical interventions for
the primary and neck lesions [6, 7], which might facilitate cancer metastasis to regional lymph
nodes and the development of ENS in the 2nd mets.
Therefore, it is very interesting to know the extent to which the neck disease-related factors,
including 1st/2nd mets, ENS in the 1st/2nd mets, and ND can contribute to the prognosis of
HNSCC patients who had undergone surgical excision of the primary lesions. Accordingly, in
the present study, we retrospectively investigated the impact of ENS in the 1st and/or 2nd mets
on the prognosis of HNSCC patients in terms of cancer-specific survival, by assessing the rela-
tive risk factors of the different profiles of 1st/2nd mets and ENS. It should be noted that, by
including the 2nd met for analysis in this study, we excluded patients who developed locore-
gional failures in the primary site and/or distant metastases during the periods from the sur-
gery up to the development of 2nd met, which did not fulfill the requirements of 2nd met.
Thus, the risks obtained in the present study were minimally influenced by post-treatment
conditions of the primary and distant metastatic lesions.
Materials and methods
Data collection
We searched the clinical databases of the Nagasaki University Hospital and identified 548
patients (373 men and 175 women; median age, 67 years; age range, 26–95 years) with HNSCC
who underwent excision of the primary tumor with or without ND [ND (+), n = 316 and ND
(-), n = 232], and were examined preoperatively and postoperatively with computed tomogra-
phy (CT) or magnetic resonance (MR) imaging for the primary and neck (metastatic node)
lesions between 1994 and 2015 (Group I, Fig 1). Patients who had distant metastasis, preceding
HNSCC history, overlapping malignancy in other parts of the body, or recurrence of the pri-
mary lesion, or had received pre-operative radiotherapy were excluded from the study cohort.
The study protocol was approved by the ethics committee of Nagasaki University Hospital, and
the requirement to obtain informed consent for the review of images and records was waved.
Primary metastatic [1st met (+), n = 151] or non-metastatic [1st met (-), n = 165] nodes
were confirmed on the pathology report of the excised ND specimens. ND (-) patients
(n = 232) were categorized in the 1st met (-) patient group. The secondary metastasis (2nd
met) was defined as a metastatic node that occurred after the initial surgical interventions for
the primary tumor without any preceding primary recurrence or distant metastasis during
the follow-up period, and that was histologically and/or clinically confirmed. The median
duration between excision of the primary tumors and the diagnosis of a 2nd met was 6 months
(range, 1–61 months). The median follow-up period of the 548 patients was 54 months (1–241
months).
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ENS-positive nodes of the 1st met were histologically (n = 54) diagnosed, and those of the
2nd met were histologically (n = 38) or clinically (n = 16, based on CT or MR imaging) diag-
nosed in 516 (346 men and 170 women; median age, 67 years; age range, 26–95 years) of the
548 HNSCC patients (Group II, Fig 1).
The primary sites of the Group I/Group II patients included the tongue (n = 180/n = 172),
lower gingiva (81/75), oral floor (50/46), hypopharynx (48/42), larynx (46/45), upper gingiva
(42/40), oropharynx (35/31), buccal mucosa (24/24), ear (12/12), maxillary sinus (9/9), palate
(9/8), lip (6/6), upper plus lower gingiva (4/4), and nasal cavity (2/2). The summary statistics
of the 548 (Group I) and 516 (Group II) patients are shown in Table 1.
Imaging criteria for 2nd met and ENS
The 2nd met was identified based on histological results from biopsy specimen or specimen
from the neck dissection for 2nd met, or on CT and/or MR imaging findings. A 2nd met with
or without ENS was identified on CT and/or MR images as a nodal structure in the neck that
fulfilled at least one of the following criteria: (a) non-enhanced focal defects in the nodal
parenchyma, (b) apparent size-up on images during follow-up periods, or (c) imaging charac-
teristics of ENS. An ENS-positive node was defined on CT and/or MR images as a nodal struc-
ture having irregular or interrupted enhancement at the perimeter on contrast-enhanced CT
and/or MR images.
Fig 1. Consort diagram shows definition and metastatic node (met) profiles of 2 patient groups
(Group I and II). Group I patients were selected from the clinical data base as those who underwent surgical
excision of primary HNSCC between 1994 and 2015, were examined preoperatively and postoperatively with
CT or MR imaging for the primary and neck lesions, and did not fit the exclusion criteria listed (78 of 598 had
died from cancer at analysis); and Group II patients were from the Group I as those who were histopatholocally
or clinically confirmed to have or have not ENS (63 of 516 had died from cancer at analysis).
https://doi.org/10.1371/journal.pone.0183611.g001
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Table 1. Demographic and clinical statistics of Group I (n = 548) and Group II (n = 516) HNSCC
patients.









men: women 373: 175 346: 170
primary site








1st met profiles in the neck (size/no./location) §
3 cm/single/ipsilateral — 44
>3 cm and6 cm/single/ipsilateral — 4
6 cm/multiple/ipsilateral — 52
6 cm/single or multiple/contralateral — 20

















head and neck SCCs 78 63
other causes ¶ 15 14
cancer in other organs 5 5
GI tract cancer 2 2
lung cancer 1 1
uterus cancer 1 1
(Continued )
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Statistical analysis
Cancer-specific survival of the patients was estimated using cumulative incidence function in
the presence of competing risk such as death due to non-SCC tumor or non-cancer deaths
(Table 1). Cumulative incidences in different patient groups were compared using Gray’s test.
The Bonferroni correction was used to adjust p-values in multiple comparisons.
Univariate and multivariable Cox proportional hazard regression analyses were used to test
for independent significance with varying combinations of the following parameters included
in the model as covariates: sex, age in grade, primary site, the presence or absence of 1st met,
the presence or absence of 2nd met, the presence or absence of ENS in the 1st met, the pres-
ence or absence of ENS in the 2nd met, and the number of ENS-positive 1st or 2nd mets. Vari-
ables with p values of<0.05 at the determination of unadjusted HRs were incorporated in
multivariable analysis to assess the adjusted HRs. The relative HRs of varying combinations
of met variables were calculated, with a particular set of combined met variables used as a
reference (HR = 1). The Cox proportional hazard regression analysis was performed on the
variables that were confirmed not to violate the proportional hazards (PH) assumption.
Schoenfeld residuals were used for assessing the violation of PH assumption. We found that
the PH assumption was not violated in all models.
Influence of pre-existing 1st met and history of ND in the same neck side of 2nd met on
cancer specific survival was estimated using Kaplan-Meier analysis, and log-rank test was
applied to assess the significance in cancer-specific survival rates between groups.
Cox proportional hazard regression analysis, and Kaplan-Meier analysis with log-rank test
were performed using JMP Pro (SAS, version 13) software. R software version 3.4.0 (2017-04-
21, https://www.R-project.org/) was used for assessing PH violations and Cumulative inci-
dence function.
Results
Prognostic importance of 1st and 2nd met
We first analyzed the prognostic importance of demographical and neck disease profiles of the
548 patients with HNSCC. Multivariable Cox proportional hazard regression analysis indi-
cated that 1st or 2nd mets were significant and independent risk factors in HNSCC patients
[adjusted HR = 2.00; 95% CI, 1.17–3.53; p = 0.01 for 1st met (+) patients, and 4.55; 95% CI,
Table 1. (Continued)
Group I (n = 548) Group II (n = 516)
bladder cancer 1 1
suicide 2 2
myocardial infarction 1 1
asthma 1 1
brain aneurysm 1 0
senility 1 1
unknown 4 4
§, Nodal size was determined on axial CT or MR images and was expressed in the maximum diameter;
location was referred as the neckside relative to the primary lesion (ipsilateral or contralateral).
¶, The primary and neck lesions were controlled and any distant metastasis was not evident in these
patients.
https://doi.org/10.1371/journal.pone.0183611.t001
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2.85–7.21; p <0.001, for 2nd met (+)].; however, age, sex, primary site, and the history of ND
were not (Table 2).
Consistent with these results, cumulative incidence function of the same 548 HNSCC
patient cohort revealed that the prognosis of HNSCC patients with 1st or 2nd met was signifi-
cantly worse than patients without nodal metastasis (p<0.0001, Gray’s test with Bonferroni
correction) (Fig 2). Furthermore, the prognosis was much worse for HNSCC patients with 1st
and 2nd mets than patients with a single type of met alone [1st met (+)/2nd met (-), p<0.0001;
1st met (-)/2nd met (+), p = 0.0078].
Prognostic importance of ENS in 1st and 2nd mets
The predictive ability of ENS in the 1st and 2nd mets for cancer-specific survival of HNSCC
patients was investigated in 516 patients with histologically or clinically confirmed ENS-positive
or ENS-negative mets. Multivariable Cox proportional hazard regression analysis indicated that
ENS in the 1st met [ENS-positive 1st met (+) vs. ENS-positive 1st met (-), adjusted HR = 3.15;
95% CI, 1.40–7.56; p = 0.006] and 2nd met [ENS-positive 2nd met (+) vs. ENS-positive 2nd met
(-), adjusted HR = 4.03; 95% CI, 1.41–16.96; p = 0.007] were both significant and independent
predictors of poor prognosis, but the 1st met and 2nd met per se were not (Table 3).
Table 2. Cox proportional hazard regression analysis for important prognostic factors in 548 HNSCC patients (Group I).
n hazards ratio 95% CI p-value
univariate analysis






gender (men vs. women) 373/175 2.16 1.25–4.01 0.005
primary site
hypopharynx vs. larynx 48/46 4.04 1.45–14.25 0.007
hypopharynx vs. oropharynx 48/35 3.55 1.16–15.41 0.02
hypopharynx vs. oral cavity 48/396 2.29 1.22–4.00 0.01
hypopharynx vs. miscellaneous 48/23 2.90 0.95–12.60 0.06
hypopharynx vs. others 48/500 2.49 1.34–4.30 0.005
1st met (+) vs. 1st met (-) 151/397 3.29 2.11–5.16 <0.001
2nd met (+) vs. 2nd met (-) 95/453 4.59 2.92–7.16 <0.001
ND (+) vs. ND (-) 316/232 2.50 1.51–4.35 <0.001
multivariable analysis
gender (men vs. women) 373/175 1.43 0.81–2.72 0.23
primary site (hypopharynx vs. others) 48/500 1.90 0.996–3.64 0.051
1st met (+) vs. 1st met (-) 151/397 2.00 1.17–3.53 0.01
2nd met (+) vs. 2nd met (-) 95/453 4.55 2.85–7.21 <0.001
ND (+) vs. ND (-) 316/232 1.59 0.82–3.10 0.17
HNSCC, head and neck squamous cell carcinoma; 1st met, primary metastasis; 2nd met, secondary metastasis; ENS, extranodal spread; 95% CI, 95%
confidence interval, ND, neck dissection. Patients were categorized into either of the age groups of29, 30–49, 50–69, 70–89, or90 years. In
multivariable analysis, adjusted hazards ratios were estimated by incorporating variables that were significant in univariate analysis. n, numbers of patients.
https://doi.org/10.1371/journal.pone.0183611.t002
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Relative risks of ENS in 1st and 2nd mets
Next, we investigated the relative risks of ENS that appeared solely in the 1st or 2nd met, or
that appeared in both the 1st and 2nd mets. Cumulative incidence function revealed that the
cancer-specific survival of ENS-positive 1st met (+)/ENS-positive 2nd met (-) or ENS-positive
1st met (-)/ENS-positive 2nd met (+) patients was significantly lower than that of patients
without ENS (p = 0.0003 and p<0.0001, respectively; Gray’s test with Bonferroni correction)
(Fig 3A and 3B). However, the difference in survival between the groups with either type of
ENS-positive met did not quite reach the significance level (p = 0.052). In contrast, patients
with ENS double-positive mets [ENS-positive 1st met (+)/ENS-positive 2nd met (+)] had a sig-
nificantly worse prognosis than patients with either type of ENS-positive met [p = 0.0004 for
vs. ENS-positive 1st met (+)/ENS-positive 2nd met (-), and p = 0.0031 for vs. ENS-positive 1st
met (-)/ENS-positive 2nd met (+)].
Fig 2. Cumulative incidence function in 548 HNSCC patients with different 1st and 2nd met profiles.
The number of cases at risk (no. at risk) at each time point (0–200 months) was provided in B. Gray’s test was
used to compare cumulative incidences between different groups. The Bonferroni correction was used to
adjust p-values in multiple comparisons in the Gray’s test and a difference in survival probability between 2
curves with a p-value of <0.0083 (= 0.05/6) was considered significant. p <0.0001 for patient groups with 1st
met (-)/2nd met (-) vs. 1st met (+)/2nd met (-), or 1st met (-)/2nd met (+), or 1st met (+)/2nd met (+), and 1st
met (+)/2nd met (-) vs. 1st met (+)/2nd met (+); p = 0.0078 for patient groups with 1st met (-)/2nd met (+) vs.
1st met (+)/2nd met (+); p = 0.222 for patient groups with 1st met (+)/2nd met (-) vs. 1st met (-)/2nd met (+).
https://doi.org/10.1371/journal.pone.0183611.g002
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To further evaluate the relative importance of ENS-positive 1st and 2nd mets as a prognos-
tic variable of HNSCC patients, we determined the relative HRs for patients with various ENS
met profiles (Fig 4). Cox proportional hazard regression analysis showed that the relative HRs
of ENS-positive 1st met (+)/ENS-positive 2nd met (-) and of ENS-positive 1st met (-)/ENS-
positive 2nd met (+) patients were 4.02 (95% CI, 1.78–8.24; p = 0.002) and 8.29 (95% CI, 4.58–
Table 3. Cox proportional hazard regression analysis for the prognostic impact of ENS-positive 1st or 2nd mets on 516 patients (Group II).
n hazard ratio 95% CI p-value
univariate analysis
primary site
hypopharynx vs. others 42/474 2.18 1.04–4.10 0.04
1st met
size/number/location§
3 cm/single/ipsi vs. 1st met (-) 44/391 2.41 1.09–4.77 0.03
3< and 6 cm/single/ipsi vs. 1st met (-) 4/391 2.23 x 10−9 0–7.38 0.46
6 cm/multiple/ipsi vs. 1st met (-) 52/391 2.44 1.19–4.62 0.02
6 cm/single or multiple/contra vs. 1st met (-) 20/391 3.47 1.19–8.09 0.03
>6 cm vs. 1st met (-) 5/391 2.21 x 10−9 0–3.01 0.25
6 cm/multiple/ipsi vs.3 cm/single/ipsi 52/44 1.01 0.42–2.52 0.97
1st met (+) vs. 1st met (-) 125/391 2.35 1.40–3.88 0.002
number of ENS-positive 1st met
1 vs. 0 39/462 2.99 1.37–5.83 0.008
2 vs. 0 15/462 6.43 2.65–13.35 <0.001
2 vs. 1 15/39 2.15 0.77–5.78 0.14
2/1 vs. 0 54/462 3.91 2.14–6.77 <0.001
2nd met
number of 2nd met
1 vs. 0 53/437 4.89 2.69–8.58 <0.001
2 vs. 0 26/437 9.83 4.83–18.79 <0.001
2 vs. 1 26/53 2.01 0.94–4.19 0.07
2/1 vs. 0 79/437 6.09 3.69–10.02 <0.001
number of ENS-positive 2nd met
1 vs. 0 44/462 7.30 4.18–12.41 <0.001
2 vs. 0 10/462 13.13 4.94–29.28 <0.001
2 vs. 1 10/44 1.80 0.66–4.23 0.23
2/1 vs. 0 54/462 8.08 4.85–13.31 <0.001
multivariable analysis
primary site
hypopharynx vs. others 42/474 1.71 0.80–3.34 0.16
1st met
1st met (+) vs. 1st met (-) 125/391 1.06 0.48–2.09 0.89
ENS-positive 1st met (+) vs. ENS-positive 1st met (-) 54/462 3.15 1.40–7.56 0.006
2nd met
2nd met (+) vs. 2nd met (-) 79/437 2.01 0.48–5.63 0.29
ENS-positive 2nd met (+) vs. ENS-positive 2nd met (-) 54/462 4.03 1.41–16.96 0.007
Cox proportional hazard regression analysis was performed in 516 HNSCC patients who were selected from the original 548 patients as those having
histologically (1st mets) and histologically or clinically (2nd mets) confirmed ENS-positive or -negative mets. 95% CI, 95% confidence interval. Two
variables that are separated by ‘vs.’ were compared.
§, Mets were categorized into those that had occurred in the neck sides ipsilateral (ipsi) or contralateral (contra) to the primary lesions.
https://doi.org/10.1371/journal.pone.0183611.t003
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14.76; p<0.001), respectively. The relative ratio was further increased to 25.80 (95% CI, 10.15–
57.69; p<0.001) in patients with ENS double-positive mets.
Influence of 1st met and/or ND history for ENS-positive 2nd met
development
Lastly, we asked whether the history of 1st met and ND can affect the prognosis of patients
with 2nd met. To this end, we compared the survival probability between patients with or
without a history of 1st met in a patient group having histologically and/or clinically confirmed
2nd met(s) (n = 95, see Group 1 in Fig 1). This patient subcohort did not include any compet-
ing risks. Therefore, we used Kaplan-Meier analysis instead of the cumulative incidence func-
tion for assessing the survival probability. The analysis indicated that the survival probability
of patients with 2nd met in the neck side where a preceding 1st met had occurred and the
Fig 3. Cumulative incidence function for assessing the influence of ENS on prognoses in 516 HNSCC
patients with different ENS-positive met profiles. The number of cases at risk (no. at risk) at each time
point (0–200 months) was provided in B. The Bonferroni correction was used to adjust p-values in multiple
comparisons in the Gray’s test and a difference in survival probability between 2 curves with a p-value of
<0.0083 (= 0.05/6) was considered significant. p <0.0001 for patient groups without ENS (ENS-negative) vs.
ENS-positive 1st met (-)/ENS-positive 2nd met (+) [ENS-positive 2nd met (+)], or ENS-positive 1st met
(+)/ENS-positive 2nd met (+) [ENS-positive 1st met (+)/2nd met (+)]; p = 0.0003 for ENS-negative patient
group vs. ENS-positive 1st met (+)/ENS-positive 2nd met (-) [ENS-positive 1st met (+)]; p = 0.0004 for ENS-
positive 1st met (+) patient group vs. ENS-positive 1st met (+)/2nd met (+) patient group; p = 0.0031 for ENS-
positive 2nd met (+) group vs. ENS-positive 1st met (+)/2nd met (+) group; and p = 0.052 (not significant) for
ENS-positive 1st met (+) group vs. ENS-positive 2nd met (+) group.
https://doi.org/10.1371/journal.pone.0183611.g003
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subsequent ND performed was significantly lower than that of patients with 2nd met in the
neck without any history of 1st met (p = 0.003, Fig 5A and 5B).
A further investigation using a limited study population of patients with ENS-positive or
ENS-negative 2nd met (n = 79, see Group II in Fig 1) showed significantly different occur-
rence rates of ENS-positive 2nd met in the neck with preceding 1st met and ND, from those
with ND history alone, and those without any history of 1st met or ND (p = 0.008, Cochran-
Armitage test, Fig 5C).
Discussion
In the present study, we investigated the relative risks of ENS in the 1st and 2nd mets as prog-
nostic factors in HNSCC patients who underwent surgical excision of the primary tumors. We
found that ENS in the 1st and 2nd mets were the dominant risk factors in patients over other
tested factors, including age, sex, primary site, ND history, and the profiles (numbers and loca-
tions in the neck) of 1st and 2nd mets. An ENS-positive 2nd met carried a similar prognostic
risk level as ENS-positive 1st met; however, the double-positive ENS in the 1st and 2nd mets in
the same neck indicated a much worse prognosis than the presence of either type of ENS-posi-
tive met. Furthermore, a preceding 1st met with an ND history was a risk factor of ENS-posi-
tive 2nd met in the same neck side.
As mentioned in the methods section, the 2nd met was defined as one that occurred in the
absence of primary tumor recurrence and distant metastasis. Therefore, patients having such
histories were tentatively categorized into the 2nd met (-) group in the present study, and the
assessment for risk factors was conducted under the assumption that the primary lesions were
kept under control during the periods from the surgery up to the development of 2nd met.
However, in previous studies, the prognostic outcomes had been greatly affected by the condi-
tions of the primary lesions [1, 2]. Thus, the present results suggest that the prognosis of
Fig 4. Hazard ratios from Cox proportional hazard analysis. Hazard ratios were calculated with ENS-
positive 1st met (-)/ENS-positive 2nd met (-) patient group [including 1st met (-)/2nd met (-), 1st met (+)/ENS-
positive 1st met (-)/2nd met (-), and 1st met (-)/2nd met (+)/ENS-positive 2nd met (-) groups] used as a
reference (hazard ratio = 1.00) of the other patient groups. *, p = 0.002 for groups with ENS-positive 1st met
(-)/ENS-positive 2nd met (-) vs. ENS-positive 1st met (+)/ENS-positive 2nd met (-); **, p <0.001 for groups
with ENS-positive 1st met (-)/ENS-positive 2nd met (-) vs. ENS-positive 1st met (-)/ENS-positive 2nd met (+),
and ENS-positive 1st met (+)/ENS-positive 2nd met (+) (log-rank test). Numerical data in parentheses
indicate 95% confidence intervals.
https://doi.org/10.1371/journal.pone.0183611.g004
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HNSCC patients who had undergone excisions of the primary tumors can exclusively depend
on the ENS profiles of 1st and 2nd mets provided the primary lesions are controlled.
The prognostic importance of ENS has been controversial for patients with HNSCC. For
example, de Juan et al. showed that knowing the the presence or absence of ENS in the ND
improved the predictive ability of tumor-node-metastasis (TNM) classification in HNSCC
patients [8]. However, Sinha et al. did not find any evidence that ENS could be predictive in
patients with p16-positive oropharyngeal SCC [9]. More recently, Wreesmann et al. has shown
that prognosis depended upon the extent of ENS beyond the nodal capsules, and that the prog-
nosis of oral SCC patients with minor (1.7 mm beyond the capsule) ENS-positive node was
not different from that of patients without ENS-positive nodes [10]. The heterogeneity of the
patient populations in terms of HNSCC primary sites may be another factor contributing to
the observed discrepancies. In the present study, we used patients with a relatively wide spec-
trum of HNSCC primary sites. However, Shingaki et al. analyzed the risk factors in a more
homogeneous patient population (oral cavity SCC) to show that ENS was a significant predic-
tor for patient survival, albeit with borderline significance in multivariable analysis [11]. It is
plausible that SCCs in the different primary tumor sites grow, invade the surrounding organs,
and metastasize to regional lymph nodes in different ways. Consistent with this idea, it is well
known that the hypopharynx has a rich mucosal and submucosal lymphatic capillary network
[12]. Accordingly, hypopharyngeal SCC has a high propensity for metastasizing to regional
lymph nodes. In the present study, the primary site (hypopharynx and oral cavity) was found
Fig 5. Influence of pre-existing 1st met and history of ND in the same neck side of 2nd met. A, B, Kaplan-Meier analysis in
95 HNSCC patients with 2nd mets. The number of cases at risk (no. at risk) at each time point (0–120 months) was provided in
B. p <0.003 for patient groups with (neck with 1st met) vs. without (neck without 1st met) preceding 1st met and ND in the same
neck side of 2nd met (log-rank test). C, Correlations between ENS in 2nd mets and 1st met and/or ND history in the same neck
sides of 79 HNSCC patients with 2nd met. ENS-positive rates were calculated for patient groups with different profiles of 1st met
and ND history, including 1st met (+)/ND (+), 1st met (-)/ND (+), and 1st met (-)/ND (-). p = 0.008 for different groups (Cochran-
Armitage test).
https://doi.org/10.1371/journal.pone.0183611.g005
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to be an important factor for the occurrence of ENS-positive 2nd mets, but was not an inde-
pendent predictor of poor prognosis. In this regard, the recently updated criteria for the N-
classification of oral SCC incorporated ENS as a critical item, but not for the classification of
other HNSCC subtypes [13].
Multiple occurrences of ENS-positive 1st mets have been indicated as higher-risk factor
in patients with HNSCC compared to a single occurrence of an ENS-positive met [14, 15].
However, the present study did not support this concept. Instead, the occurrence of ENS-posi-
tive met at different stages (i.e., 1st and 2nd mets) in a single HNSCC patient significantly
decreased the cancer-specific survival. The present study demonstrated that ENS in the 1st and
2nd mets was the dominant risk factors to the HNSCC patient, and that even the profiles of 1st
and 2nd mets did not independently and significantly affect the patient outcomes. However,
the present results should be carefully interpreted, considering that we did not verify (1) the
influence of the different treatment types performed, (2) p16 expression, a prognostic marker,
for predicting prognosis of oropharyngeal cancer, and (3) the T classification specific for dif-
ferent primary sites as a possible prognostic factor [8, 9]. The notion that ENS is the dominant
prognostic factor could be verified by assessing the prognostic outcomes of oral SCC patients
who are categorized into subgroups according to the new N classification system, and then
analyzing the ENS profiles in the 1st and 2nd mets within each group.
It should also be noted that the preexisting 1st met with ND history could be a risk factor in
patients with ENS-positive 2nd met. The significantly higher rates of ENS-positive 2nd met
in the patient group with a preexisting 1st met(s) and ND history within the same neck
sides than in the group without these neck profiles (94% vs. 62%) suggest that the neck with
these histories might be prone to developing ENS-positive mets. At this time, it is not well
understood how ENS occurs in mets. Sumi and Nakamura showed that fibrotic foci were
found in the immediate vicinity of ruptured nodal capsules of SCC nodes in the neck, and
that those areas often contained cancer cell nests [16]. Intratumoral fibrotic foci are thought
to indicate hypoxic areas [17]. Considering the current consensus that intratumoral hypoxic
conditions could promote aggressive tumor growth [18], detection of intranodal hypoxia
might facilitate the early and precise detection of ENS-positive mets with capsular ruptures.
In terms of molecular mechanisms leading to ENS, recent studies have evaluated a possible
role for lysyl oxidase in tumor hypoxia [19]. Furthermore, a close relationship between lysyl
oxidases and ErbB2 signaling has been implicated as a molecular mechanism of nodal rup-
ture [20, 21].
This study is partly limited by its retrospective nature. First, surgical excision of the primary
lesions without preoperative radiotherapy was one of the inclusion criteria, but protocols for
post-operative chemoradiotherapy (radiation doses and chemotherapy protocols) and ND
types (radical, selective, or extended radical) were not fully controlled for in the present study.
Second, all the 1st mets were histologically confirmed, but 2nd mets were clinically diagnosed
on CT/MR images in 16 of the 79 patients. Although CT/MR imaging diagnosis of mets with
ENS produced acceptable results [16, 22, 23], a very small number of false-positive and false-
negative results could not be avoided. Third, we did not assess T classification for predicting
patient prognosis. We studied a HNSCC patient cohort with widely varying primary sites. The
T classification is defined differently for HNSCCs in different primary sites. Therefore, the
importance of T classification should be separately evaluated in HNSCC patients with different
primary sites, even if it means decreasing the cohort size [24].
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